The Tyrosine Kinase Inhibitor Dasatinib impedes adaptive cell surveillance in peripheral lymph nodes

被引：0
|
作者：
Carvoeiro, Daniela Claudino [1 ]
Marcos-Jimenez, Ana [2 ]
Munoz-Calleja, Cecilia [2 ,3 ]
Stein, Jens Volker [1 ]
机构：
[1] Univ Fribourg, Dept Oncol Microbiol & Immunol, Fribourg, Switzerland
[2] La Princesa Hosp IIS IP, Biomed Res Inst, Dept Immunol, Madrid, Spain
[3] Inst Salud Carlos III, CIBER Infect Dis CIBERINFECC, Madrid, Spain
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2024年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
1435 - P2.
引用
收藏
页码：1099 / 1099
页数：1
相关论文
共 50 条
  • [21] Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2
    Eltayeb, Sara
    Dressler, Julia M.
    Schlatt, Lukas
    Pernecker, Moritz
    Neugebauer, Ute
    Karst, Uwe
    Ciarimboli, Giuliano
    ARCHIVES OF TOXICOLOGY, 2024, 98 (07) : 2131 - 2142
  • [22] Stable Fatty Acid Solvates of Dasatinib, a Tyrosine Kinase Inhibitor: Prediction, Process, and Physicochemical Properties
    Saladi, Venkata Narasayya
    Kammari, Bal Raju
    Maruthapillai, Arthanareeswari
    Mahapatra, Sudarshan
    Chennuru, Ramanaiah
    Sajja, Eswaraiah
    Rajan, Srinivasan Thirumalai
    Mathad, Vijayavitthal T.
    ACS OMEGA, 2022, 7 (08): : 7032 - 7044
  • [23] Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
    Mustjoki, S.
    Ekblom, M.
    Arstila, T. P.
    Dybedal, I.
    Epling-Burnette, P. K.
    Guilhot, F.
    Hjorth-Hansen, H.
    Hoglund, M.
    Kovanen, P.
    Laurinolli, T.
    Liesveld, J.
    Paquette, R.
    Pinilla-Ibarz, J.
    Rauhala, A.
    Shah, N.
    Simonsson, B.
    Sinisalo, M.
    Steegmann, J. L.
    Stenke, L.
    Porkka, K.
    LEUKEMIA, 2009, 23 (08) : 1398 - 1405
  • [24] The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation
    Sita Virakul
    Virgil A. S. H. Dalm
    Dion Paridaens
    Willem A. van den Bosch
    Nattiya Hirankarn
    P. Martin van Hagen
    Willem A. Dik
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252 : 1101 - 1109
  • [25] Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy
    Mustjoki, Satu
    Ekblom, Marja
    Arstila, T. Petteri
    Dybedal, Ingunn
    Epling-Burnette, P. K.
    Garzon, Felix
    Gedde-Dahl, Tobias
    Hernesniemi, Sari
    Hjorth-Hansen, Henrik
    Hoglund, Martin
    Juvonen, Vesa
    Kairisto, Veli
    Kovanen, Panu
    Kreutzman, Anna
    Laurinolli, Tuisku
    Liesveld, Jane
    Paquette, Ronald
    Pinilla, Javier
    Rauhala, Auvo
    Shah, Neil
    Simonsson, Bengt
    Sinisalo, Marjatta
    Luis Steegmann, Juan
    Stenke, Leif
    Vakkila, Jukka
    Porkka, Kimmo
    BLOOD, 2008, 112 (11) : 215 - 215
  • [26] Effect of the SRC tyrosine kinase inhibitor dasatinib in combination with erlotinib and in cells with acquired resistance to erlotinib
    Haura, E.
    Gao, J.
    Li, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 182 - 182
  • [27] The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation
    Virakul, Sita
    Dalm, Virgil A. S. H.
    Paridaens, Dion
    van den Bosch, Willem A.
    Hirankarn, Nattiya
    van Hagen, P. Martin
    Dik, Willem A.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 252 (07) : 1101 - 1109
  • [28] Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
    S Mustjoki
    M Ekblom
    T P Arstila
    I Dybedal
    P K Epling-Burnette
    F Guilhot
    H Hjorth-Hansen
    M Höglund
    P Kovanen
    T Laurinolli
    J Liesveld
    R Paquette
    J Pinilla-Ibarz
    A Rauhala
    N Shah
    B Simonsson
    M Sinisalo
    J L Steegmann
    L Stenke
    K Porkka
    Leukemia, 2009, 23 : 1398 - 1405
  • [29] cKIT overexpression and wild-type NRAS/BRAF predict response to the tyrosine kinase inhibitor dasatinib in melanoma cell lines
    Journe, F.
    Wiedig, M.
    Morandini, R.
    Sales, F.
    Ghanem, G.
    Awada, A.
    EJC SUPPLEMENTS, 2010, 8 (07): : 83 - 84
  • [30] cKIT expression level and NRAS/BRAF mutation status predict the response to the tyrosine kinase inhibitor dasatinib in melanoma cell lines
    Journe, F.
    Wiedig, M.
    Morandini, R.
    Sales, F.
    Awada, A.
    Ghanem, G.
    PIGMENT CELL & MELANOMA RESEARCH, 2011, 24 (04) : 801 - 801
12345